WAYNE, Pa.--(BUSINESS WIRE)--The importance of immunophenotyping for the proper diagnosis and management of patients with hematolymphoid neoplasia necessitates the development of guidelines for the appropriate performance of these techniques in the clinical laboratory. The newly published edition of Clinical and Laboratory Standards Institute’s (CLSI, formerly NCCLS) document, Clinical Flow Cytometric Analysis of Neoplastic Hematolymphoid Cells; Approved Guideline—Second Edition (H43-A2), addresses issues of safety, specimen collection and transportation, sample preparation, immunofluorescent staining, instrument quality control, data acquisition, and data storage for the application of flow cytometry to the immunophenotypic analysis of these disorders.
